Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.42% | -6.76% | 72.18% | 50.36% | 47.04% |
| Total Depreciation and Amortization | 434.44% | 540.60% | 61.80% | 158.93% | 155.63% |
| Total Amortization of Deferred Charges | -2.90% | -31.46% | -21.40% | -33.44% | -35.99% |
| Total Other Non-Cash Items | 41.96% | 64.57% | 6.95% | 5.17% | 19.40% |
| Change in Net Operating Assets | -60.99% | 649.48% | -290.23% | -67.65% | -485.42% |
| Cash from Operations | -27.73% | 219.21% | 65.13% | 40.40% | -30.72% |
| Capital Expenditure | 300.00% | -10.01% | -- | -- | 81.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 156.94% | -2.25% | 139.24% | 66.53% | 86.77% |
| Cash from Investing | 157.52% | -2.28% | 139.20% | 67.13% | 86.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -49.73% | 137.67% | -98.70% | -98.49% | -95.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -54.70% | 3,071.36% | -98.70% | -98.49% | -95.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.95% | 141.81% | 102.07% | -84.00% | -450.41% |